Table Info

Table 4.

Analyses for predictors of a new diagnosis of epilepsy during follow-up

Characteristic	Epilepsy (N = 3)	No epilepsy (N = 47)	p comparing groups	p univariate regression
Sex (male)	67%	64%	1.00	0.92
Lobar ICH	33%	19%	0.50	0.56
Smoking	33%	15%	0.41	0.42
Diabetes	33%	28%	1.00	0.85
Hypertension	100%	92%	1.00	1.00
Anticoagulation	0%	28%	0.36	1.00
mRS at discharge (median, IQR)	0 (0)	0 (1)	0.64
Age, years (median, IQR)	58.3 (0)	73.0 (12.3)	0.047	0.058

ICH: intracerebral hemorrhage; IQR: interquartile range; mRS: modified Rankin Scale

Declarations

Author contributions

JOTS: Conceptualization, Investigation, Data curation, Formal analysis, Methodology, Project administration, Supervision, Validation, Visualization, Writing—original draft, Writing—review & editing. JT: Investigation, Supervision, Writing—review & editing. JP, LB, M Hassan, M Heikkinen, AK, AM, AMS, and JW: Investigation, Writing—review & editing. AMK: Formal analysis, Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

Jussi O.T. Sipilä, who is the Editorial Board Member of Exploration of Neuroscience, had no involvement in the decision-making or the review process of this manuscript. Jussi O.T. Sipilä: Honoraria (Novartis), Congress attendance support (Lundbeck), Advisory Board (Sandoz, Boehringer-Ingelheim), Shareholder (Orion). Ayla Mehdiyeva: Congress attendance support (Sanofi). Mohamed Hassan: Congress attendance support (Merck). Johanna Willman: Congress attendance support (Orion). Anne-Mari Kantanen: Advisory board (Boehringer-Ingelheim, Astra-Zeneca), Congress Attendance support Astra Zeneca. All other authors declare that they have no conflicts of interest.

Ethical approval

This study involves no direct contact (outside of normal healthcare procedures) with the patients, and ethical approval is therefore not required according to Finnish law.

Consent to participate

This study involves no direct contact (outside of normal healthcare procedures) with the patients or publishing identifiable individual level information, and patient consent is therefore not required according to Finnish law.

Consent to publication

Not applicable.

Availability of data and materials

These data are subject to restrictions by Finnish law. Access can be applied for from Siun Sote (https://www.siunsote.fi/web/english/contact-information).

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

McGurgan IJ, Ziai WC, Werring DJ, Al-Shahi Salman R, Parry-Jones AR. Acute intracerebral haemorrhage: diagnosis and management. Pract Neurol. 2020;21:128–36. [DOI] [PubMed] [PMC]

Arboix A, Massons J, Oliveres M, García L, Titus F. An analysis of 1000 consecutive patients with acute cerebrovascular disease. The registry of cerebrovascular disease of La Alianza-Hospital Central of Barcelona. Med Clin (Barc). 1993;101:281–5. Spanish. [PubMed]

Pinho J, Costa AS, Araújo JM, Amorim JM, Ferreira C. Intracerebral hemorrhage outcome: A comprehensive update. J Neurol Sci. 2019;398:54–66. [DOI] [PubMed]

Jolink WM, Klijn CJ, Brouwers PJ, Kappelle LJ, Vaartjes I. Time trends in incidence, case fatality, and mortality of intracerebral hemorrhage. Neurology. 2015;85:1318–24. [DOI] [PubMed]

Béjot Y, Grelat M, Delpont B, Durier J, Rouaud O, Osseby G, et al. Temporal trends in early case-fatality rates in patients with intracerebral hemorrhage. Neurology. 2017;88:985–90. [DOI] [PubMed]

Carlsson M, Wilsgaard T, Johnsen SH, Vangen-Lønne AM, Løchen ML, Njølstad I, et al. Temporal Trends in Incidence and Case Fatality of Intracerebral Hemorrhage: The Tromsø Study 1995–2012. Cerebrovasc Dis Extra. 2016;6:40–9. [DOI] [PubMed] [PMC]

Sivenius J, Tuomilehto J, Immonen-Räihä P, Kaarisalo M, Sarti C, Torppa J, et al.; FINSTROKE study. Continuous 15-year decrease in incidence and mortality of stroke in Finland: the FINSTROKE study. Stroke. 2004;35:420–5. [DOI] [PubMed]

Sipilä JOT, Ruuskanen JO, Kauko T, Rautava P, Kytö V. Seasonality of stroke in Finland. Ann Med. 2017;49:310–8. [DOI] [PubMed]

Meretoja A, Kaste M, Roine RO, Juntunen M, Linna M, Hillbom M, et al. Trends in treatment and outcome of stroke patients in Finland from 1999 to 2007. PERFECT Stroke, a nationwide register study. Ann Med. 2011;43:S22–30. [DOI] [PubMed]

10.

Fogelholm R, Murros K, Rissanen A, Avikainen S. Long term survival after primary intracerebral haemorrhage: a retrospective population based study. J Neurol Neurosurg Psychiatry. 2005;76:1534–8. [DOI] [PubMed] [PMC]

11.

Sipilä JOT, Ruuskanen JO, Rautava P, Kytö V. Case fatality of hospital-treated intracerebral hemorrhage in Finland—A nationwide population-based registry study. J Neurol Sci. 2021;425:117446. [DOI] [PubMed]

12.

Parry-Jones AR, Järhult SJ, Kreitzer N, Morotti A, Toni D, Seiffge D, et al. Acute care bundles should be used for patients with intracerebral haemorrhage: An expert consensus statement. Eur Stroke J. 2024;9:295–302. [DOI] [PubMed] [PMC]

13.

Li X, Zhang L, Wolfe CDA, Wang Y. Incidence and Long-Term Survival of Spontaneous Intracerebral Hemorrhage Over Time: A Systematic Review and Meta-Analysis. Front Neurol. 2022;13:819737. [DOI] [PubMed] [PMC]

14.

Ueno H, Tokugawa J, Saito R, Yamashiro K, Tsutsumi S, Yamamoto M, et al.; Juntendo Registry of Spontaneous Intracerebral Hemorrhage Study Group. Trends in prior antithrombotic medication and risk of in-hospital mortality after spontaneous intracerebral hemorrhage: the J-ICH registry. Sci Rep. 2024;14:12009. [DOI] [PubMed] [PMC]

15.

Siepen BM, Forfang E, Branca M, Drop B, Mueller M, Goeldlin MB, et al. Intracerebral haemorrhage in patients taking different types of oral anticoagulants: a pooled individual patient data analysis from two national stroke registries. Stroke Vasc Neurol. 2024;9:640–51. [DOI] [PubMed] [PMC]

16.

Hellman T, Salo H, Kulathinal S, Eloranta P, Airaksinen J, Laine J. Use of oral anticoagulants among patients with atrial fibrillation in 2015–2017—a register study. Finnish Med J. 2020;47:2531–7. Finnish.

17.

Foschi M, D’Anna L, Gabriele C, Conversi F, Gabriele F, De Santis F, et al. Sex Differences in the Epidemiology of Intracerebral Hemorrhage Over 10 Years in a Population-Based Stroke Registry. J Am Heart Assoc. 2024;13:e032595. [DOI] [PubMed] [PMC]

18.

Lahti AM, Huhtakangas J, Juvela S, Bode MK, Tetri S. Increased mortality after post-stroke epilepsy following primary intracerebral hemorrhage. Epilepsy Res. 2021;172:106586. [DOI] [PubMed]

19.

Boulanger M, Al-Shahi Salman R, Kerssens J, Wild SH; Scottish Diabetes Research Network Epidemiology Group. Association between diabetes mellitus and incidence of intracerebral haemorrhage and case fatality rates: A retrospective population-based cohort study. Diabetes Obes Metab. 2017;19:1193–7. [DOI] [PubMed]

20.

Muñoz-Rivas N, Méndez-Bailón M, Hernández-Barrera V, de Miguel-Yanes JM, Jimenez-Garcia R, Esteban-Hernández J, et al. Type 2 Diabetes and Hemorrhagic Stroke: A Population-Based Study in Spain from 2003 to 2012. J Stroke Cerebrovasc Dis. 2016;25:1431–43. [DOI] [PubMed]

21.

Carlsson M, Wilsgaard T, Johnsen SH, Johnsen LH, Løchen ML, Njølstad I, et al. Long-Term Survival, Causes of Death, and Trends in 5-Year Mortality After Intracerebral Hemorrhage: The Tromsø Study. Stroke. 2021;52:3883–90. [DOI] [PubMed]

22.

Boulanger M, Poon MT, Wild SH, Al-Shahi Salman R. Association between diabetes mellitus and the occurrence and outcome of intracerebral hemorrhage. Neurology. 2016;87:870–8. [DOI] [PubMed] [PMC]

23.

Rivier CA, Renedo D, Marini S, Magid-Bernstein JR, de Havenon A, Rosand J, et al. Sex Modifies the Severity and Outcome of Spontaneous Intracerebral Hemorrhage. Ann Neurol. 2025;97:232–41. [DOI] [PubMed]

24.

Foerch C, Lo EH, van Leyen K, Lauer A, Schaefer JH. Intracerebral Hemorrhage Formation Under Direct Oral Anticoagulants: Clinical and Translational Evidence. Stroke. 2019;50:1034–42. [DOI] [PubMed]

25.

Koivunen K, Sillanpää E, Munukka M, Portegijs E, Rantanen T. Cohort Differences in Maximal Physical Performance: A Comparison of 75- and 80-Year-Old Men and Women Born 28 Years Apart. J Gerontol A Biol Sci Med Sci. 2021;76:1251–9. [DOI] [PubMed]

26.

Munukka M, Koivunen K, von Bonsdorff M, Sipilä S, Portegijs E, Ruoppila I, et al. Birth cohort differences in cognitive performance in 75- and 80-year-olds: a comparison of two cohorts over 28 years. Aging Clin Exp Res. 2021;33:57–65. [DOI] [PubMed] [PMC]

27.

Haapaniemi E, Strbian D, Rossi C, Putaala J, Sipi T, Mustanoja S, et al. The CAVE Score for Predicting Late Seizures After Intracerebral Hemorrhage. Stroke. 2014;45:1971–6. [DOI] [PubMed]

28.

Lahti AM, Saloheimo P, Huhtakangas J, Salminen H, Juvela S, Bode MK, et al. Poststroke epilepsy in long-term survivors of primary intracerebral hemorrhage. Neurology. 2017;88:2169–75. [DOI] [PubMed]

29.

Ebbesen MQB, Dreier JW, Andersen G, Johnsen SP, Christensen J. Stroke and Risk of Epilepsy: A Danish Nationwide Register-Based Study. Stroke. 2024;55:972–82. [DOI] [PubMed]

30.

Wu T, Lv C, Wu L, Chen W, Lv M, Jiang S, et al. Risk of intracranial hemorrhage with direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Neurol. 2022;269:664–75. [DOI] [PubMed]

31.

Lin DS, Lo HY, Huang KC, Lin TT, Lee JK. Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2023;12:e030380. [DOI] [PubMed] [PMC]

32.

Wang S, Zou XL, Wu LX, Zhou HF, Xiao L, Yao T, et al. Epidemiology of intracerebral hemorrhage: A systematic review and meta-analysis. Front Neurol. 2022;13:915813. [DOI] [PubMed] [PMC]

33.

Lv M, Wu T, Jiang S, Chen W, Zhang J. Risk of Intracranial Hemorrhage Caused by Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation (from a Network Meta-Analysis of Randomized Controlled Trials). Am J Cardiol. 2022;162:92–9. [DOI] [PubMed]

34.

Hald SM, Möller S, García Rodríguez LA, Al-Shahi Salman R, Sharma M, Christensen H, et al. Trends in Incidence of Intracerebral Hemorrhage and Association With Antithrombotic Drug Use in Denmark, 2005–2018. JAMA Netw Open. 2021;4:e218380. [DOI] [PubMed] [PMC]

35.

Tobacco statistics [Internet]. Helsinki: Finnish Institute for Health and Welfare; c2025 [cited 2025 Jun 3]. Available from: https://thl.fi/en/statistics-and-data/statistics-by-topic/alcohol-drugs-and-addiction/tobaccostatistics

36.

Numminen H, Kotila M, Waltimo O, Aho K, Kaste M. Declining Incidence and Mortality Rates of Stroke in Finland From 1972 to 1991: Results of Three Population-Based Stroke Registers. Stroke. 1996;27:1487–91. [DOI] [PubMed]

37.

Tuomilehto J, Rastenyte D, Sivenius J, Sarti C, Immonen-Räihä P, Kaarsalo E, et al. Ten-Year Trends in Stroke Incidence and Mortality in the FINMONICA Stroke Study. Stroke. 1996;27:825–32. [DOI] [PubMed]

38.

Teppo K, Airaksinen KEJ, Jaakkola J, Halminen O, Salmela B, Kouki E, et al. Ischaemic stroke in women with atrial fibrillation: temporal trends and clinical implications. Eur Heart J. 2024;45:1819–27. [DOI] [PubMed] [PMC]

39.

Lehtonen A, Salomaa V, Immonen-Räihä P, Sarti C, Mähönen M, Tuomilehto J, et al. Declining incidence and mortality of stroke in persons aged ≥ 75 years in Finland; the FINSTROKE study. Eur J Cardiovasc Prev Rehabil. 2004;11:466–70. [PubMed]

40.

Arboix A, Rodríguez-Aguilar R, Oliveres M, Comes E, García-Eroles L, Massons J. Thalamic haemorrhage vs internal capsule-basal ganglia haemorrhage: clinical profile and predictors of in-hospital mortality. BMC Neurol. 2007;7:32. [DOI] [PubMed] [PMC]